reports
Q1 2024 Revenue and Business Update
Q1 2024 Revenue and Business Update MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M), an increase of 18% on the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s prostate cancer imaging product Illuccix®. U.S. revenue grew by 18% to US$111.8M...
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imagingCollaboration agreement announced for joint development and commercialisation with UCSF PharmaLogic announced as commercial manufacturing and pharmacy distribution partner MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma ima...
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder...
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma probe used to detect radiation in patients and guide surgery. The patient was operated on at Hospital del Mar in Barcelona, Spain. SENSEI® is smaller than an AA battery and designed specifica...
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmac...
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH (ABX-CRO), a full-service contract research organization (CRO) based in Dresden, and its development partner, Stockholm-based Quantinm AB. QDOSE® is a validated, versatile softwar...
Appointment of Dr Darren Patti to Group Chief Operating Officer
Appointment of Dr Darren Patti to Group Chief Operating Officer MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024. Dr. Patti joined Telix in March 2021 to lead the Company’s United States (U.S.) operations. Over the past three years as U.S. Chief Operating Officer and General Manager for the Americas region he has overseen the successful launches of Illuccix® in the U.S. and Canada, has led ongoing m...
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platf...
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production. ARTMS, based in Burnaby, British Columbia (BC), Canada, is a privately held, venture-backed company, which specialises in...
Telix Expands U.S. Development and Manufacturing Infrastructure with A...
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics MELBOURNE, Australia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services ...
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenu...
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline MELBOURNE, Australia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023. All figures are in AUD$ unless otherwise stated.1 2023 highlights Total Group revenue of $502.5M, an increase of 214% from $160.1M in 2022 primarily driven by continued strong growth in sales of Illuccix® in the second year since commerci...
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer ...
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer. 153Sm-DOTMP is a novel kit-based bone-seeking targeted radiopharmaceutical candidate that u...
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers ...
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024) MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024. Dr David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to present updates on our late-stage therapeutic programs for pro...
Telix Announces Planned Registered Public Offering and Listing in the ...
Telix Announces Planned Registered Public Offering and Listing in the United States MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix” or the “Company”) today announces that it is considering an initial public offering (“IPO”) of American Depositary Shares (“ADSs”) representing its ordinary shares in the United States (“U.S.”) and listing on the Nasdaq Global Market (“Nasdaq”). Telix’s ordinary shares will remain listed on the Australian Securities Exchange. The number of ADSs that may be offered, the number of underlying ordinary shar...
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference MELBOURNE, Australia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (US). The presentation will take place on Tuesday 9 January at 3:00pm PST (6:00pm EST / 10:00am AEDT, 10 January). Participants can register for the webcast at the following . The webcast will be accessible on demand on the Telix web...
Telix Pharmaceuticals Limited: 1 director
A director at Telix Pharmaceuticals Limited bought 51,305 shares at 6.693AUD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
- Thomas J. Schiessle
Solide Basis – Finanzierungsreichweite (Mitte 2025) bis zum angestrebt...
Wie erwartet, wurde die Finanzplanung vor dem Hintergrund der strategischen Zusammenarbeit mit dem Pharma-Multi Huadong Medicine (Huadong) und der abgeschlossenen Barkapitalerhöhung aktualisiert. Der Cash-Reach weitet sich deutlich auf „Mitte 2025“. Angestrebte zusätzliche Partnerschaften (jüngst mit Chiome Bioscience), wie auch angestrebte Erfolgsprämien aus dem Heritage-Portfolio sind darin nicht enthalten. Die Entwicklungsfortschritte in den ATAC®-Programmen bzw. in der wachsenden Zahl der P...
Telix Radiopharmaceutical Production Facility Buildout Commences
Telix Radiopharmaceutical Production Facility Buildout Commences MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of Belgium. The state-of-the-art facility will serve as the primary European manufacturing site for Telix’s products, aligning with the Group’s strategic objective of maintaining control and reliability of its supply chain, as well ...
EAU Updates Guidance for PSMA-PET Imaging
EAU Updates Guidance for PSMA-PET Imaging MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the updated 2022 ‘Guidelines on Prostate Cancer’ (the Guidelines) from the European Association of Urology (EAU), which demonstrate an increasing recognition of the clinical utility of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging modalities (PSMA PET), including gallium-68 PSMA-11, in the diagnosis of prostate cancer.1 The EAU Guidelines are dedicated to the devel...
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolmen...
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) a pivotal Phase III study of investigational renal (kidney) cancer imaging agent TLX250-CDx has dosed 252 patients, the target enrolment for the study. TLX250-CDx (89Zr-DFO-girentuximab) is an investigational product for the imaging of clear cell renal cell carcinoma (ccRCC) with position emission tomography (PET). TLX250...
Telix and SHINE partner for Lutetium-177 Supply
Telix and SHINE partner for Lutetium-177 Supply MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for highly pure no-carrier-added (n.c.a.) lutetium-177 (177Lu), a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation (MTR) investigational products. As Telix advances its late-stage clinical trials using the medical radioisotope 177Lu, it is building a global supplier networ...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supp...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) for highly pure no-carrier-added (n.c.a.) lutetium-177 (177Lu), a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation (MTR) investigational products. This agreement further enhances Telix’s existing 177Lu supplier network, which in...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Im...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Athens-based BIOKOSMOS S.A. (BIOKOSMOS) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the Greek and Cypriot markets. Under the terms of the agreement, BIOKOSMOS will be the overall distrib...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.